Sasha Damouni Ellis | Vice President of Corporate Affairs and Investor Relations |
Scott Braunstein | Chairman and Chief Executive Officer |
Christy Shafer | Chief Commercial Officer |
Alex Aimetti | Chief Scientific Officer |
Steven Pfanstiel | Chief Financial Officer and Chief Operating Officer |
Michael Dougherty | Director |
Andrew Tsai | Jefferies |
Charles Duncan | Cantor Fitzgerald |
Brian Abrahams | RBC Capital Markets |
Joseph Thome | TD Cowen |
Douglas Tsao | H.C. Wainwright |
Brian Skorney | Baird |
Joon Lee | Truist Securities |
Mark Goodman | SVB Securities |
Jay Olson | Oppenheimer |
Michael Higgins | Ladenburg Thalmann |
Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session.
And now it is my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations.
You may begin Ms.